News

Zacks Investment Research on MSN6d
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
Pharmabiz7d
China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration
China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration: Berlin Friday, May 23, 2025, 09:00 Hrs [IST] The Center for Drug Evaluation (CDE) of China’s Nationa ...
Morningstar1mon
EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal ...
EYLEA® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...
Seeking Alpha1mon
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly ...
EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...
WCBD1mon
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...